Kainos Laboratories, Inc. (JP:4556)
:4556
4556 Stock Chart & Stats
¥1271.00
¥2.00(0.16%)
At close: 4:00 PM EST
¥1271.00
¥2.00(0.16%)
Day’s Range― - ―
52-Week Range¥1,035.00 - ¥2,284.00
Previous CloseN/A
Volume2.10K
Average Volume (3M)3.67K
Market Cap
¥9.25B
Enterprise Value¥2.52B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)9.5
Beta0.55
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.53%
Share Statistics
EPS (TTM)105.98
Shares Outstanding4,558,860
10 Day Avg. Volume3,280
30 Day Avg. Volume3,666
Financial Highlights & Ratios
PEG Ratio-62.73
Price to Book (P/B)0.78
Price to Sales (P/S)1.00
P/FCF Ratio8.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowVery strong free cash flow growth and near-1:1 conversion of net income into FCF indicate durable internal funding for R&D, capex, and dividends. High cash conversion improves strategic flexibility and reduces reliance on external financing over the next several quarters.
Conservative Balance SheetVery low leverage and a high equity ratio provide financial resilience versus cyclical pressures. This conservative capital structure supports sustained investment in product development and weathering of reimbursement or demand shocks without materially increasing financing risk.
Robust Profitability And MarginsHigh gross and healthy operating margins reflect durable pricing power or efficient production for diagnostic reagents. Consistent margin structure supports steady cash generation and the ability to reinvest in product pipelines or maintain returns to shareholders over multiple quarters.
Bears Say
Modest Revenue GrowthRevenue expansion appears modest, limiting the company's ability to scale fixed-cost absorption and meaningfully grow profits without scope expansion. Sustained low top-line growth could constrain long-term margin expansion and the pace of reinvestment into new products or markets.
Concentrated Product FocusA narrow focus on diagnostic reagents concentrates revenue risk on a limited product set and end-market. Structural shifts in testing protocols, reimbursement, or competitor assay adoption could materially affect results; diversification or new product platforms would reduce this exposure.
Small Organizational ScaleA small workforce can limit commercial reach, regulatory capabilities, and R&D throughput versus larger peers. Scale disadvantages may slow international expansion, limit bargaining power with distributors, and make rapid capacity scaling or multi-market launches harder over the medium term.
4556 FAQ
What was Kainos Laboratories, Inc.’s price range in the past 12 months?
Kainos Laboratories, Inc. lowest stock price was ¥1035.00 and its highest was ¥2284.00 in the past 12 months.
What is Kainos Laboratories, Inc.’s market cap?
Kainos Laboratories, Inc.’s market cap is ¥9.25B.
When is Kainos Laboratories, Inc.’s upcoming earnings report date?
Kainos Laboratories, Inc.’s upcoming earnings report date is May 08, 2026 which is in 40 days.
How were Kainos Laboratories, Inc.’s earnings last quarter?
Kainos Laboratories, Inc. released its earnings results on Jan 27, 2026. The company reported ¥105.98 earnings per share for the quarter, beating the consensus estimate of N/A by ¥105.98.
Is Kainos Laboratories, Inc. overvalued?
According to Wall Street analysts Kainos Laboratories, Inc.’s price is currently Overvalued.
Does Kainos Laboratories, Inc. pay dividends?
Kainos Laboratories, Inc. pays a Annually dividend of ¥32 which represents an annual dividend yield of 2.53%. See more information on Kainos Laboratories, Inc. dividends here
What is Kainos Laboratories, Inc.’s EPS estimate?
Kainos Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kainos Laboratories, Inc. have?
Kainos Laboratories, Inc. has 4,558,860 shares outstanding.
What happened to Kainos Laboratories, Inc.’s price movement after its last earnings report?
Kainos Laboratories, Inc. reported an EPS of ¥105.98 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.357%.
Which hedge fund is a major shareholder of Kainos Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:4556
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kainos Laboratories, Inc.
KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.